Niagen Bioscience, Inc. (NASDAQ: NAGE) reported Q2 EPS of $0.01, $0.01 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $29.8 million versus the consensus estimate of $32.18 million.

For earnings history and earnings-related data on Niagen Bioscience, Inc. (NAGE) click here.